GlassScriptPhysician profile
Michelle M Bauer
NPI 1750463071
$5,278.22
in general payments reported to CMS, 2019-2025
36 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $176 · 2022: $11.80 · 2023: $1,434 · 2024: $1,348 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,428.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.67 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $573.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $523.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $324.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Axsome Therapeutics, INC. | $295.93 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $294.14 | 2023-2024 | Quviviq |
| Pfizer INC. | $257.01 | 2019-2025 | |
| Exact Sciences Corporation | $256.54 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $177.56 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $166.30 | 2019 | |
| Phathom Pharmaceuticals, INC. | $160.87 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.88 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $153.79 | 2023-2025 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $127.97 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.76 | 2019-2025 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $119.60 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $118.24 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $116.49 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Janssen Biotech, INC. | $88.54 | 2025 | Tremfya, Simponi, Simponi Aria |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.11 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $56.11 | 2019-2020 | |
| Astellas Pharma US INC | $55.94 | 2023-2025 | Veozah |
| Antares Pharma, INC. | $50.78 | 2022-2025 | Xyosted |
| Dexcom, INC. | $48.62 | 2023 | Dexcom G6 Transmitter |
| Halozyme INC | $31.02 | 2023 | |
| Phadia US INC. | $30.72 | 2023-2024 | Immunocap |
| Amgen INC. | $27.49 | 2019 | |
| Allergan, INC. | $27.29 | 2020 | |
| Shield Therapeutics INC | $26.02 | 2025 | |
| Grifols USA, LLC | $23.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.60 | 2019 | |
| Tolmar, INC. | $19.11 | 2025 | Jatenzo |
| Cranial Technologies, INC | $18.72 | 2023 | Doc Band |
| Currax Pharmaceuticals LLC | $15.42 | 2024 | Contrave |
| Scilex Pharmaceuticals INC. | $14.51 | 2019 | |
| Ibsa Pharma INC. | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.